Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-14: Phase 2 study of alternative dosing regimens of belantamab mafodotin in relapsed or refractory multiple myeloma
2021-004151-16Phase 2Active
- Sponsor
- GSK
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of belantamab mafodotin in multiple myeloma (MM) (3 arms), sponsored by GSK. Primary endpoint: Incidence rate of Grade ≥2 ocular adverse events (KVA scale). Started Oct 2021; status: active.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-004151-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004151-16.